What is HC Wainwright’s Estimate for LRMR FY2025 Earnings?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – HC Wainwright lowered their FY2025 earnings estimates for Larimar Therapeutics in a report issued on Tuesday, March 25th. HC Wainwright analyst E. White now forecasts that the company will earn ($1.91) per share for the year, down from their previous estimate of ($1.77). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ FY2026 earnings at ($2.10) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.16).

Several other equities analysts have also recently issued reports on the company. Truist Financial started coverage on Larimar Therapeutics in a research note on Wednesday, January 29th. They issued a “buy” rating and a $18.00 price objective for the company. Robert W. Baird decreased their price target on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Guggenheim reissued a “buy” rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a research report on Tuesday. Eleven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Larimar Therapeutics currently has an average rating of “Buy” and an average target price of $20.22.

Larimar Therapeutics Trading Up 5.6 %

NASDAQ:LRMR opened at $2.38 on Thursday. Larimar Therapeutics has a 12-month low of $2.19 and a 12-month high of $11.20. The firm has a market cap of $151.54 million, a PE ratio of -2.07 and a beta of 0.99. The stock has a fifty day moving average price of $3.10 and a 200 day moving average price of $5.16.

Hedge Funds Weigh In On Larimar Therapeutics

Several hedge funds have recently made changes to their positions in LRMR. BNP Paribas Financial Markets acquired a new stake in shares of Larimar Therapeutics in the 4th quarter valued at about $25,000. Algert Global LLC acquired a new stake in shares of Larimar Therapeutics in the fourth quarter valued at approximately $47,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Larimar Therapeutics during the fourth quarter worth approximately $52,000. Graham Capital Management L.P. acquired a new position in shares of Larimar Therapeutics in the 4th quarter valued at $54,000. Finally, ProShare Advisors LLC purchased a new stake in Larimar Therapeutics in the 4th quarter valued at $58,000. Hedge funds and other institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.